Phacilitate Leaders World


Ed Pezella

Ed Pezella

Former National Medical Director, Pharmacy Policy and Strategy, Aetna

Edmund Pezalla, M.D., MPH, is Aetna’s National Medical Director for Pharmaceutical Policy and Strategy. He is responsible for the integration of pharmacy policy and activities into Aetna’s overall strategy and operations. Dr. Pezalla also serves as the lead clinical spokesperson for Aetna in pharmacy related issues and represents Aetna on industry work groups and conferences.

Dr. Pezalla is Aetna’s leading executive on pharmaceutical development, reimbursement strategy and drug evaluation. He is active on projects with the IOM, CDC and FDA as well as MIT’s Center for Biomedical Innovation.

Dr. Pezalla was an invited expert contributing to the President’s Council of Advisors on Science and Technology report: Propelling Innovation in Drug Discovery, Development and Evaluation. In 2014 Dr. Pezalla served as Aetna’s interim Chief Medical Officer for SEHA, the Qatari National Health Insurance Scheme.

Dr. Pezalla is a graduate of Georgetown University College of Arts and Sciences, and Georgetown University School of Medicine. He holds an MPH from the University of California at Berkeley and was a research fellow and doctoral student in Health Management and Policy at the University of Michigan.

  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman